{
    "clinical_study": {
        "@rank": "163184", 
        "arm_group": {
            "arm_group_label": "Probiotic Lactobacillus reuteri Vs Placebo", 
            "arm_group_type": "Experimental", 
            "description": "patients with full arch with dental implant received a tablet of Lactobacillus reuteri every day during 28 days, and after a wash-up, the same patients receive a tablet of placebo every day during 28 days"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study was evaluate the effects of the oral probiotic Lactobacillus reuteri\n      Prodentis upon the peri-implant health of edentulous patients with dental implants and\n      peri-implant mucositis, establishing comparisons versus implants without peri-implant\n      disease. The hypothesis of the study is that using these probiotics are going to improve the\n      periimplant health."
        }, 
        "brief_title": "Use of Probiotics in Oral Health of Patients With Dental Implants", 
        "completion_date": {
            "#text": "July 2010", 
            "@type": "Actual"
        }, 
        "condition": "Mucositis", 
        "condition_browse": {
            "mesh_term": "Mucositis"
        }, 
        "detailed_description": {
            "textblock": "A double-blind, placebo-controlled, prospective cross-over study was made. All the patients\n      were edentulous and were divided into two groups: A) with no peri-implant disease; B) with\n      peri-implant mucositis affecting one or more implants. Patients with peri-implantitis were\n      excluded. All patients in both groups initially received the oral probiotic Lactobacillus\n      reuteri Prodentis, followed by placebo. Only the supervisor of the study knew this\n      information; clinical examiner and patients were blind. Were studied: crevicular fluid\n      volume, modified plaque index, probing depth, modified gingival index, and concentrations of\n      interleukin 1\u03b2, interleukin 6 and interleukin 8, and Bacterial load."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Totally edentulous patients subjected to dental implant rehabilitation in one or both\n             arches\n\n          -  Prosthetic restoration in function for at least 24 months\n\n          -  Healthy individuals without known disease\n\n        Exclusion Criteria:\n\n          -  Patients receiving any kind of local or systemic decontamination treatment of the\n             oral cavity (e.g., antibiotics or rinses) in the last 3 months, or periodontal\n             treatment in the last 6 months\n\n          -  Uncontrolled periodontal disease\n\n          -  Patients with immune deficiencies, diabetes, rheumatoid disease, head and neck\n             radiotherapy, bisphosphonate treatment, chemotherapy or anticoagulation\n\n          -  Patients with dental implants presenting intraoral exposure of the rough portion of\n             any implant\n\n          -  Smokers\n\n          -  Incomplete protocols due to a lack of patient cooperation: a) failure to follow the\n             treatment instructions; b) failure to report to the visit after one month of\n             follow-up\n\n          -  Failure to provide informed consent to participation the study\n\n          -  Patients presenting at least one implant with peri-implantitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974596", 
            "org_study_id": "Probiotics"
        }, 
        "intervention": [
            {
                "arm_group_label": "Probiotic Lactobacillus reuteri Vs Placebo", 
                "intervention_name": "Probiotic tablets of Lactobacillus reuteri", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "strains of Lactobacillus reuteri ATCC PTA 5289 - 100 million", 
                    "Strains of Lactobacillus reuteri DSM 17938 - 100 million"
                ]
            }, 
            {
                "arm_group_label": "Probiotic Lactobacillus reuteri Vs Placebo", 
                "intervention_name": "Placebo tablets", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Placebo tablets with same visually aspect, flavour and texture than the probiotic but without probiotic strains"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dental implants", 
            "Probiotics", 
            "Lactobacillus reuteri", 
            "Periimplant mucositis", 
            "Cytokines", 
            "Bacterial load"
        ], 
        "lastchanged_date": "October 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Valencia", 
                    "country": "Spain", 
                    "zip": "46010"
                }, 
                "name": "Department of Oral Surgery, University of Valencia"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "THE EFFECT OF ORALLY ADMINISTERED PROBIOTIC LACTOBACILLUS REUTERI-CONTAINING TABLETS IN PERI-IMPLANT MUCOSITIS: A RANDOMIZED CLINICAL TRIAL", 
        "other_outcome": {
            "description": "Where evaluate Aggregatibacter and red complex of socransky", 
            "measure": "Evidence of reduction of Total Bacterial Load studied", 
            "safety_issue": "Yes", 
            "time_frame": "28 days using probiotic tablets/day"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The Mombelli clasification was used to evaluate the reduction of bacterial plaque. 0: No bacterial plaque; 1: presence of bacterial plaque but not visually; 2: 1/3 part of the implant with bacterial plaque; 3: 2/3 parts or more of the implant with bacterial plaque", 
            "measure": "Evidence in reduction of plaque index", 
            "safety_issue": "Yes", 
            "time_frame": "28 days using one probiotic tablet/day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974596"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Valencia", 
            "investigator_full_name": "Antonio Juan Flichy Fern\u00e1ndez", 
            "investigator_title": "DDS, Colaborator University of Valencia", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The Mombelli classification was used to evaluate the reduction of bleeding around implants: 0: no bleeding; 1: a point of bleeding; 2)a line of bleeding; 3: much bleeding", 
                "measure": "Evidence in reduction of bleeding around implants", 
                "safety_issue": "Yes", 
                "time_frame": "28 days using probiotic tablet/day"
            }, 
            {
                "description": "Was measured in reduction of millimeters of the depth of the implant with a millimeter probe.", 
                "measure": "Evidence in reduction of probing depth", 
                "safety_issue": "Yes", 
                "time_frame": "28 days using one probiotic tablet/day"
            }, 
            {
                "description": "concentration measured in picograms/milliliter (pg/ml)", 
                "measure": "Evidence in reduction Interleukin 1\u03b2 concentration", 
                "safety_issue": "Yes", 
                "time_frame": "28 days using one probiotic tablet/day"
            }, 
            {
                "description": "concentration measured in picograms/milliliter (pg/ml)", 
                "measure": "Evidence in reduction Interleukin 6 concentration", 
                "safety_issue": "Yes", 
                "time_frame": "28 days using one probiotic tablet/day"
            }, 
            {
                "description": "concentration measured in picograms/milliliter (pg/ml)", 
                "measure": "Evidence in reduction Interleukin 8 concentration", 
                "safety_issue": "Yes", 
                "time_frame": "28 days using one probiotic tablet/day"
            }
        ], 
        "source": "University of Valencia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Valencia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}